NCT06971081 (DENT-DOAC) is a NA clinical trial of LED light in Direct Oral Anticoagulants (DOACs), sponsored by University College, London.

Who is sponsoring NCT06971081?

NCT06971081 is sponsored by University College, London.

What drugs are being tested in NCT06971081?

Interventions in NCT06971081: LED light.

What condition does NCT06971081 study?

NCT06971081 studies Direct Oral Anticoagulants (DOACs).

Is NCT06971081 still recruiting?

NCT06971081 is currently active, enrolled. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT06971081: DENT-DOAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LED Application Following Dental Extraction in Patients Taking Direct Oral Anticoagulants.

Active, enrolled NA Last updated 14 May 2025

What this trial tests

NA trial testing LED light in Direct Oral Anticoagulants (DOACs) in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 August 2023

Primary endpoint
30 June 2025

30 June 2025

Quick facts

Lead sponsor	University College, London
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	50
Start date	17 August 2023
Primary completion	30 June 2025
Estimated completion	30 June 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

LED light

Conditions studied

Direct Oral Anticoagulants (DOACs) — all drugs for Direct Oral Anticoagulants (DOACs) →

Sponsor

University College, London

Who can join

Adults 18 to 80, any sex, with Direct Oral Anticoagulants (DOACs). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The DENT-DOAC trial is a single-blinded RCT investigating the effectiveness of LED application following dental extractions in patients taking direct oral anticoagulants (DOACs) . The study aims to address a significant clinical challenge, as bleeding following dental extraction is a well-recognized complication in patients taking anticoagulants, and the number of patients taking DOACs requiring dental procedures has increased substantially in recent years. The trial will be conducted at the Eastman Dental Hospital (EDH-UCLH) and will recruit 50 participants who will be randomly divided into two groups of 25 each. The test group will receive both LED light application and haemostatic sponge treatment, while the control group will receive only the haemostatic sponge. The study population will include patients taking DOACs (rivaroxaban, apixaban, edoxaban, or dabigatran) and are scheduled for dental extraction. Exclusion criteria include patients using concomitant antithrombotic drugs, those with known allergy to tranexamic acid, pregnant or breastfeeding females, and those recently involved in other research studies. The trial's primary objective is to assess bleeding outcomes in these patients, with secondary objectives including evaluation of bleeding events (early/delayed; minor/moderate/severe) and analysis of associations between bleeding complications and various factors such as type of DOACs, surgical factors, and patient demographics. The statistical design has been carefully calculated to achieve 90% power to detect both a 50% difference in bleeding events and a 142-second difference in mean bleeding time between groups, with considerations made for a 10% drop-out rate. Patient follow-up will include immediate post-procedure assessment and telephone assessments on days 2 and 7 following the extraction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of LED light

Trials testing the same drug.

NCT03279003 — Study of the Efficacy and Tolerance of Light Therapy in Sensitive Skin · NA · completed

Other recruiting trials for Direct Oral Anticoagulants (DOACs)

Currently open trials in the same condition.

NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
NCT07309848 — Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs · recruiting

Other University College, London trials

Trials by the same sponsor.

NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06971081 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University College, London
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06971081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing